Could a leukemia drug help treat rare lung disease LAM? new trial launches
NCT ID NCT06889168
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial is testing the long-term safety of imatinib (Gleevec), a drug already approved for leukemia, in 20 women with lymphangioleiomyomatosis (LAM), a rare cystic lung disease. Participants will take either imatinib or a placebo twice daily for 6 months, with regular check-ups. The goal is to see if imatinib is safe and tolerable over a longer period, building on earlier short-term results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imatinib (Gleevec)
What this could lead to
If successful, this could point toward a new treatment option for LAM, a rare lung disease, by showing that imatinib is safe and tolerable over 6 months.
What could go wrong
This is a very early, small phase 1 trial with only 20 participants, so results may not apply to everyone. The study focuses on safety, not yet on effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHANGIOLEIOMYOMATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••